Umbilical cord mesenchymal stem cell exosome treatment for male pattern hair loss in young men
Official title: A Randomized Controlled Clinical Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes
Run by Shenzhen People's Hospital · NCT07203599 · Data updated 2026-11-12
This trial will test whether injections of umbilical cord mesenchymal stem cell exosomes can regrow hair or slow hair loss in men aged 18–35 with androgenic alopecia compared with topical 5% minoxidil.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 35 Years |
| Sex | Men only |
| Enrollment | 59 (estimated) |
| Sponsor | Shenzhen People's Hospital Academic / other |
| Locations | 1 site (Shenzhen, Guangdong) |
| Status | Recruiting |
| Started | September 20, 2025 |
| Main results expected | October 1, 2026 |
| Study ends | November 1, 2026 |
| Registry record updated | December 2, 2025 |
| Trial ID | NCT07203599 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men aged 18–35 with clinically diagnosed androgenic alopecia (Hamilton‑Norwood III–V) who can consent and meet the trial's health and medication restrictions are ideal candidates.
✕Probably not a fit
Patients outside the age range, with other scalp diseases, severe systemic illness, recent use of hair-loss drugs, or contraindicated medications are unlikely to qualify or derive benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study has a Phase I dose-escalation portion to identify a safe and tolerable injection dose of human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-sEV) and a Phase II randomized controlled portion comparing the selected dose against topical 5% minoxidil. In Phase I, participants are assigned to one of three dosing groups to determine appropriate injection density per square centimeter of hair loss. Phase II randomizes eligible participants to receive either hUCMSC-sEV injections or the comparator and follows hair growth and safety outcomes over a defined follow-up period. Safety monitoring will include adverse event reporting and clinical exams, while efficacy will be measured by standardized hair counts, photographic assessment, and scalp evaluations.
Why it matters
Potential benefit: If successful, the treatment could offer a new option to stimulate hair regrowth or slow progression of male pattern hair loss with a biologic regenerative approach.
How similar studies have gone: Preclinical studies and small early-phase clinical reports suggest stem cell-derived exosomes may promote hair growth, but large randomized clinical data are currently limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Male patients aged 18-35 2. Clinically diagnosed with androgenic alopecia, Hamilton Norwood Scale III-V 3. Patients who voluntarily participate in clinical trials and sign informed consent forms Exclusion Criteria: * 1\. Known alcohol allergy 2. Patients with severe primary diseases of cardiovascular, cerebrovascular, liver, kidney, endocrine, or hematopoietic system 3. Patients with other scalp diseases or hair loss diseases 4. Patients with severe mental illness and cognitive impairment 5. Patients with poor nutritional status and low immune function 6. Within 1 year, those who have used systemic corticosteroids, immunosuppressants, cytotoxic drugs, and peripheral vasodilators 7. Within 6 months, those who have used systemic or local drugs to treat hair loss, such as finasteride, minoxidil, etc 8. Within 3 months, those who have received other clinical trial drugs 9. Family genetic history or other criteria considered unsuitable by researchers
Where it's running
-
Shenzhen People's Hospital
Shenzhen, Guangdong, China Recruiting
Study contacts
- Study coordinator: Jianglin Zhang, Ph.D
- Email: zhang.jianglin@szhospital.com
- Phone: +86 13873143466
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dual treatment with KeraFactor and Revian LED for female pattern hair loss
This study tests whether using a scalp-stimulating serum together with a Revian LED cap helps women with androgenic alopecia grow more hair than each treatment alone or placebo.
-
Two hair supplements for men with androgenic alopecia
This study tests two daily hair supplement formulations against placebo to see if they improve hair growth and perceived hair quality in men with mild to moderate androgenetic alopecia over 84 days.
-
JAK2 levels in balding and non-balding scalp before and after topical minoxidil
This will test whether three months of topical minoxidil changes JAK2 protein levels in the scalps of adults (18–50) with mild to moderate androgenetic alopecia.
-
2-Deoxy-D-ribose hydrogel versus 5% minoxidil for androgenetic alopecia
This trial will test whether a once-daily topical 2‑Deoxy‑D‑ribose hydrogel is as effective and safe as 5% minoxidil for adults aged 18 to 50 with mild to moderate androgenetic alopecia.
-
TH07 topical treatment for male pattern hair loss
This trial will test whether a new daily topical spray called TH07 helps men aged 18–49 with male pattern hair loss grow more hair than standard minoxidil or a placebo over 24 weeks.
-
Autologous hair follicle secretome treatment for androgenic alopecia
This will test whether injecting a person's own hair-follicle secretome into the scalp can help adults with androgenic alopecia grow thicker, denser hair.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.